Terms: = Ovarian cancer AND HLF, Q16534, 3131, ENSG00000108924
8 results:
1. hlf promotes ovarian cancer progression and chemoresistance via regulating Hippo signaling pathway.
Han T; Chen T; Chen L; Li K; Xiang D; Dou L; Li H; Gu Y
Cell Death Dis; 2023 Sep; 14(9):606. PubMed ID: 37709768
[TBL] [Abstract] [Full Text] [Related]
2. Transcriptomic analyses of ovarian clear-cell carcinoma with concurrent endometriosis.
Collins KE; Wang X; Klymenko Y; Davis NB; Martinez MC; Zhang C; So K; Buechlein A; Rusch DB; Creighton CJ; Hawkins SM
Front Endocrinol (Lausanne); 2023; 14():1162786. PubMed ID: 37621654
[TBL] [Abstract] [Full Text] [Related]
3. Potential role of the HOXD8 transcription factor in cisplatin resistance and tumour metastasis in advanced epithelial ovarian cancer.
Sun P; Song Y; Liu D; Liu G; Mao X; Dong B; Braicu EI; Sehouli J
Sci Rep; 2018 Sep; 8(1):13483. PubMed ID: 30194340
[TBL] [Abstract] [Full Text] [Related]
4. Napsin A and WT 1 are useful immunohistochemical markers for differentiating clear cell carcinoma ovary from high-grade serous carcinoma.
Rekhi B; Deodhar KK; Menon S; Maheshwari A; Bajpai J; Ghosh J; Shylasree ST; Gupta S
APMIS; 2018 Jan; 126(1):45-55. PubMed ID: 29266433
[TBL] [Abstract] [Full Text] [Related]
5. Long-Term Survival Analysis of Intraperitoneal versus Intravenous Chemotherapy for Primary ovarian cancer and Comparison between Carboplatin- and Cisplatin-based Intraperitoneal Chemotherapy.
Eoh KJ; Lee JY; Nam EJ; Kim S; Kim YT; Kim SW
J Korean Med Sci; 2017 Dec; 32(12):2021-2028. PubMed ID: 29115086
[TBL] [Abstract] [Full Text] [Related]
6. Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer.
Oh J; Barve M; Matthews CM; Koon EC; Heffernan TP; Fine B; Grosen E; Bergman MK; Fleming EL; DeMars LR; West L; Spitz DL; Goodman H; Hancock KC; Wallraven G; Kumar P; Bognar E; Manning L; Pappen BO; Adams N; Senzer N; Nemunaitis J
Gynecol Oncol; 2016 Dec; 143(3):504-510. PubMed ID: 27678295
[TBL] [Abstract] [Full Text] [Related]
7. Treatment monitoring of patients with epithelial ovarian cancer using invasive circulating tumor cells (iCTCs).
Pearl ML; Dong H; Tulley S; Zhao Q; Golightly M; Zucker S; Chen WT
Gynecol Oncol; 2015 May; 137(2):229-38. PubMed ID: 25769657
[TBL] [Abstract] [Full Text] [Related]
8. Going APE over ref-1.
Evans AR; Limp-Foster M; Kelley MR
Mutat Res; 2000 Oct; 461(2):83-108. PubMed ID: 11018583
[TBL] [Abstract] [Full Text] [Related]
